277 related articles for article (PubMed ID: 33191863)
21. [Bortezomib Inhibits Extranodal Natural Killer/T Cell Lymphoma, Nasal Type by Targeting NF-κB Signaling Pathway].
Li JH; Zhang L; Feng Y; Zou LQ
Sichuan Da Xue Xue Bao Yi Xue Ban; 2019 May; 50(3):311-316. PubMed ID: 31631595
[TBL] [Abstract][Full Text] [Related]
22. Silencing of SENP2 in Multiple Myeloma Induces Bortezomib Resistance by Activating NF-κB Through the Modulation of IκBα Sumoylation.
Xie H; Gu Y; Wang W; Wang X; Ye X; Xin C; Lu M; Reddy BA; Shu P
Sci Rep; 2020 Jan; 10(1):766. PubMed ID: 31964975
[TBL] [Abstract][Full Text] [Related]
23. [Effect of Celastrol Based on IRAK4/ERK/p38 Signaling Pathway on Proliferation and Apoptosis of Multiple Myeloma Cells].
Xu XM; Kang D; Zhu XY; Kong XT; Yu H; Chen XL; Jiang PJ; Ni HW
Zhongguo Shi Yan Xue Ye Xue Za Zhi; 2022 Feb; 30(1):175-182. PubMed ID: 35123623
[TBL] [Abstract][Full Text] [Related]
24. Quinone methide tripterine, celastrol, induces apoptosis in human myeloma cells via NF-κB pathway.
Tozawa K; Sagawa M; Kizaki M
Int J Oncol; 2011 Nov; 39(5):1117-22. PubMed ID: 21850367
[TBL] [Abstract][Full Text] [Related]
25. Formononetin Regulates Multiple Oncogenic Signaling Cascades and Enhances Sensitivity to Bortezomib in a Multiple Myeloma Mouse Model.
Kim C; Lee JH; Ko JH; Chinnathambi A; Alharbi SA; Shair OHM; Sethi G; Ahn KS
Biomolecules; 2019 Jul; 9(7):. PubMed ID: 31284669
[TBL] [Abstract][Full Text] [Related]
26. Inhibition of NF-κB DNA Binding Suppresses Myeloma Growth via Intracellular Redox and Tumor Microenvironment Modulation.
Bariana M; Cassella E; Rateshwar J; Ouk S; Liou HC; Heller C; Colorado I; Feinman R; Makhdoom A; Siegel DS; Heller G; Tuckett A; Mondello P; Zakrzewski JL
Mol Cancer Ther; 2022 Dec; 21(12):1798-1809. PubMed ID: 36190955
[TBL] [Abstract][Full Text] [Related]
27. Pharmacodynamic Models of Differential Bortezomib Signaling Across Several Cell Lines of Multiple Myeloma.
Ramakrishnan V; Mager DE
CPT Pharmacometrics Syst Pharmacol; 2019 Mar; 8(3):146-157. PubMed ID: 30516019
[TBL] [Abstract][Full Text] [Related]
28. TrxR1 inhibition overcomes both hypoxia-induced and acquired bortezomib resistance in multiple myeloma through NF-кβ inhibition.
Raninga PV; Di Trapani G; Vuckovic S; Tonissen KF
Cell Cycle; 2016; 15(4):559-72. PubMed ID: 26743692
[TBL] [Abstract][Full Text] [Related]
29. The in vitro effects of phospholipase D1-mTOR axis in liver fibrogenesis.
Chang Y; Xia L; Song M; Tang M; Patpur BK; Li J; Yang W; Yang C
Life Sci; 2020 Jun; 251():117595. PubMed ID: 32240681
[TBL] [Abstract][Full Text] [Related]
30. NS-398 enhances the efficacy of bortezomib against RPMI8226 human multiple myeloma cells.
Que W; Li S; Chen J
Mol Med Rep; 2013 May; 7(5):1641-5. PubMed ID: 23545701
[TBL] [Abstract][Full Text] [Related]
31. Endothelin-1 (ET-1) induces resistance to bortezomib in human multiple myeloma cells via a pathway involving the ETB receptor and upregulation of proteasomal activity.
Vaiou M; Pangou E; Liakos P; Sakellaridis N; Vassilopoulos G; Dimas K; Papandreou C
J Cancer Res Clin Oncol; 2016 Oct; 142(10):2141-58. PubMed ID: 27530445
[TBL] [Abstract][Full Text] [Related]
32. Synergistic induction of oxidative injury and apoptosis in human multiple myeloma cells by the proteasome inhibitor bortezomib and histone deacetylase inhibitors.
Pei XY; Dai Y; Grant S
Clin Cancer Res; 2004 Jun; 10(11):3839-52. PubMed ID: 15173093
[TBL] [Abstract][Full Text] [Related]
33. BAY-11-7082 induces apoptosis of multiple myeloma U266 cells through inhibiting NF-κB pathway.
Wang Y; Zhang XL; Sun CM
Eur Rev Med Pharmacol Sci; 2018 May; 22(9):2564-2571. PubMed ID: 29771406
[TBL] [Abstract][Full Text] [Related]
34. Norcantharidin enhances bortezomib-antimyeloma activity in multiple myeloma cells in vitro and in nude mouse xenografts.
Du HF; Yu LJ; Meng YF; Lv HY; Meng J; Song XN; Zhang JQ
Leuk Lymphoma; 2013 Mar; 54(3):607-18. PubMed ID: 22889356
[TBL] [Abstract][Full Text] [Related]
35. Role of phospholipases D1 and 2 in astroglial proliferation: effects of specific inhibitors and genetic deletion.
Burkhardt U; Beyer S; Klein J
Eur J Pharmacol; 2015 Aug; 761():398-404. PubMed ID: 25967349
[TBL] [Abstract][Full Text] [Related]
36. [The Inhibiting Effect of Autophagy Inhibitor ROC-325 on Multiple Myeloma].
Shi MY; Yao Y; Deng J; Yuan CL; Liu HM; Li ZY
Zhongguo Shi Yan Xue Ye Xue Za Zhi; 2021 Jun; 29(3):797-804. PubMed ID: 34105475
[TBL] [Abstract][Full Text] [Related]
37. MicroRNA-451 regulates stemness of side population cells via PI3K/Akt/mTOR signaling pathway in multiple myeloma.
Du J; Liu S; He J; Liu X; Qu Y; Yan W; Fan J; Li R; Xi H; Fu W; Zhang C; Yang J; Hou J
Oncotarget; 2015 Jun; 6(17):14993-5007. PubMed ID: 25915427
[TBL] [Abstract][Full Text] [Related]
38. Mechanisms underlying synergism between circularized tumor necrosis factor-related apoptosis inducing ligand and bortezomib in bortezomib-sensitive or -resistant myeloma cells.
Leng Y; Hu X; Li L; Nkwocha J; Satta T; Sharma K; Kmeiciak M; Zhou H; Zhang Z; Zhou L; Chen W; Grant S
Hematol Oncol; 2022 Dec; 40(5):999-1008. PubMed ID: 35789025
[TBL] [Abstract][Full Text] [Related]
39. Sequential combination of bortezomib and WEE1 inhibitor, MK-1775, induced apoptosis in multiple myeloma cell lines.
Barbosa RSS; Dantonio PM; Guimarães T; de Oliveira MB; Fook Alves VL; Sandes AF; Fernando RC; Colleoni GWB
Biochem Biophys Res Commun; 2019 Nov; 519(3):597-604. PubMed ID: 31540690
[TBL] [Abstract][Full Text] [Related]
40. Logic-Based and Cellular Pharmacodynamic Modeling of Bortezomib Responses in U266 Human Myeloma Cells.
Chudasama VL; Ovacik MA; Abernethy DR; Mager DE
J Pharmacol Exp Ther; 2015 Sep; 354(3):448-58. PubMed ID: 26163548
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]